Kenvue stock price rebounds as merger vote nears — what KVUE traders watch next
22 January 2026
1 min read

Kenvue stock price rebounds as merger vote nears — what KVUE traders watch next

New York, Jan 22, 2026, 14:43 ET — Regular session underway.

  • KVUE edged up about 2.2% to $17.77 in afternoon trading, recovering from a 1.2% drop on Wednesday
  • The deal implies roughly $18.40 per Kenvue share, based on current KMB prices, leaving a spread of about $0.64
  • Kimberly-Clark is set to release its earnings on Jan. 27, with the merger vote scheduled for Jan. 29

Kenvue Inc. shares rose about 2.2% to $17.77 on Thursday, recovering from a dip the previous day. By early afternoon, trading volume had already exceeded 43 million shares.

Investors continue to view KVUE as a vote-driven deal play. Kenvue and Kimberly-Clark shareholders are set to vote on the merger January 29, per filings. The offer includes $3.50 cash plus 0.14625 Kimberly-Clark shares for each Kenvue share. Kimberly-Clark’s stock climbed about 1.9% to $101.91, pushing the total value of the package to roughly $18.40 for Kenvue—about 64 cents above KVUE’s close on Thursday.

The gap is the merger-arbitrage spread — the difference between KVUE’s current trading price and the deal’s implied value. This spread tends to widen when investors fear delays or a possible deal collapse. If KMB’s shares rally, the spread narrows; a slide in KMB’s stock causes it to widen again.

Kenvue dropped 1.19% on Wednesday, closing at $17.38. The stock saw 40.6 million shares change hands, beating its 50-day average volume of 38.6 million, per MarketWatch data. 1

The broader market moved higher Thursday, with the SPDR S&P 500 ETF up roughly 0.8% and the Dow-focused ETF advancing about 0.9%. The consumer staples ETF edged down a bit, hinting that Kenvue’s surge was tied more to the deal than sector momentum.

In November, Kimberly-Clark and Kenvue announced their deal, targeting completion in the latter half of 2026, subject to approvals. Kenvue CEO Kirk Perry said the move “will bring greater value to our shareholders,” while board chair Larry Merlo highlighted the “significant upfront value” of the agreement. Kimberly-Clark CEO Mike Hsu called the plan one that creates “a global health and wellness leader.” 2

But the anchor might snap. Should shareholders on either side spurn the deal, or if regulators and courts stall, KVUE stands to lose the takeover premium that’s been fueling its stock. That could send shares tumbling hard.

Kimberly-Clark will report its fourth-quarter and full-year 2025 results on Jan. 27. The company intends to release the materials around 6:30 a.m. ET, with an analyst Q&A scheduled for 8:00 a.m. ET. 3

With most of the deal tied to KMB stock, any sharp move in Kimberly-Clark’s shares after earnings could swiftly change the spread. Traders remain watchful for last-minute proxy filings, investor campaigns, or fresh legal updates before the Jan. 29 meetings.

KVUE’s trading is essentially a countdown. Keep an eye on Jan. 27, when Kimberly-Clark releases its earnings, and Jan. 29, the day shareholders vote on the merger. Those dates could make the spread tighten—or stretch out again.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
McCormick stock tumbles as MKC flags tariff costs and a softer 2026 profit outlook
Previous Story

McCormick stock tumbles as MKC flags tariff costs and a softer 2026 profit outlook

Applied Digital (APLD) stock slips after it breaks ground on 430-MW “AI factory” campus
Next Story

Applied Digital (APLD) stock slips after it breaks ground on 430-MW “AI factory” campus

Go toTop